To evaluate a multicentre series of robot-assisted partial nephrectomy (RAPN) performed for the treatment of large angiomyolipomas (AMLs).
Introduction
Angiomyolipomas (AMLs) are benign renal tumours that contain adipose tissue, smooth muscle, and weak vasculature that are prone to rupture and haemorrhage [1] . Although most patients with AML remain asymptomatic [2] , the risk for life-threatening bleeding increases with lesion size [3, 4] . Traditionally, a diameter of >4 cm has been considered an indication for prophylactic treatment [5] ; however, this threshold has been debated with reports showing that most large AMLs may be slow growing and asymptomatic [6] . According to the 2016 European Association of Urology guidelines, treatment should be considered in patients with 'large' AMLs, females of childbearing age, and patients with limited access to emergency care [7] .
Selective arterial embolisation (SAE) and nephron-sparing surgery (NSS) are acceptable treatment options for AML in the elective setting. SAE is an appealing option for management due to its less invasive nature; however, there are no prospective trials comparing outcomes of SAE and NSS. A recent literature review summarised 524 cases of SAE for AML and found a relatively favourable safety profile of the procedure, but after a median follow-up of 39 months, 21% of the patients required repeat SAE or surgery [8] .
While NSS represents a more invasive treatment than SAE, it may offer a more durable outcome. Recurrence of sporadic AML after NSS is rare, reported in 0-3% of cases [9, 10] . However, most data on the outcomes of NSS for AML are derived from open surgical series rather than contemporary minimally invasive approaches (laparoscopic or robot assisted). Moreover, the few minimally invasive NSS series that have been published are limited to small and mainly asymptomatic AMLs, which were treated due to suspicion for malignant disease and found to be AML on final surgical pathology.
Large AMLs may pose a significant surgical challenge. The fragile tissue, the irregular morphology, and the lack of a well-defined surgical plane between the AML and the rest of the kidney may add to the surgical complexity; however, surgical margins are less of a concern. In the present study, we report the surgical outcomes of robot-assisted partial nephrectomy (RAPN) performed for the treatment of large AMLs.
Patients and Methods
We retrospectively reviewed all electively performed RAPN for renal AMLs between 2005 and 2016 at five academic centres in the USA. Institutional Review Board approval was received by each participating centre. All patients underwent preoperative evaluation with either CT or MRI. Patients with symptomatic AMLs or AMLs of >4 cm in maximal diameter were included. Renal masses suspicious for malignancy and ultimately found to be lipid-poor AMLs on final pathology were not included. Medical records were reviewed and patients' characteristics were recorded (age, sex, body mass index, haematocrit, creatinine, estimated GFR [eGFR], comorbidities, AML-related symptoms, and history of prior SAE). Nephrometry score [11] was calculated based on preoperative imaging studies.
Surgery
All RAPN shared the basic steps that have been previously described for RAPN [12] . A transperitoneal approach in the flank position was used by all surgeons with a five-port configuration (12-mm camera port, three 8-mm robotic ports and a 12-mm assistant port). Renal ischaemia was achieved either by clamping of the renal artery and vein or the renal artery alone. If a non-ischaemic approach was undertaken, the renal hilum was dissected circumferentially and a vessel loop was placed for vascular control if needed. Haemostasis was achieved with cautery and with the aid of argon-beam coagulation. Pneumoperitoneum was maintained at a maximal pressure of 15-20 mmHg.
Outcome Measures and Statistical Analysis
A descriptive analysis of patient demographics and surgical details was performed. Surgical details included intraoperative (operative time, ischaemia time, estimated blood loss [EBL], intraoperative complications) and postoperative (change in haematocrit, postoperative complications, hospital stay, change in renal function) results. Continuous variables were reported using medians and interquartile ranges (IQRs), while discrete variables were reported using proportions. Renal function was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [13] . The percentage change in eGFR on follow-up was calculated as: (eGFR preoperative À eGFR postoperative ) 9 100/eGFR preoperative . Comparative tests (chi-square for discrete variables, MannWhitney test for ordinal and continuous variables) were used to assess for differences in surgical outcomes of patients who underwent SAE before RAPN and those who did not. Statistical tests were two-sided and were considered statistically significant when P < 0.05. Analyses were performed with Stata 10© (Stata Corp., College Station, TX, USA).
Results
In all, 40 eligible patients were identified at five participating institutions (Cleveland Clinic, University of Chicago, Tulane University, Indiana University, and Fox Chase Cancer Center). All specimens were pathologically confirmed as AML. A summary of patient demographics and preoperative data is presented in Table 1 . The median (IQR) age was 54 (45-63) years and 31 (78%) were females. Six patients (15%) had a history of tuberous sclerosis and 11 (28%) had . Two patients progressed from stage 2 CKD to stage 3 CKD, but the overall median eGFR preservation rate was 95%. None of the patients developed AML-related symptoms or recurrence during follow-up. Table 3 presents the surgical results of 11 patients who underwent SAE before RAPN compared to patients who did not. The median (IQR) time between SAE and RAPN was 10 (8-18) months. The indication for surgery after SAE failure was bleeding (two patients), abdominal pain (two patients) and increasing tumour size or lack of size reduction (seven patients). Patients with prior SAE had lower preoperative eGFRs and higher tumour nephrometry scores (P = 0.03). There were no statistically significant differences in operative time or WIT. The rate of non-clamping cases in the prior SAE group and the non-SAE group was four of 11 and four of 29 (14%), respectively (P = 0.2). No blood transfusions or postoperative embolisations were required in the prior SAE group. On follow-up, there was no eGFR reduction in the SAE subgroup and a median eGFR reduction of 8% in the non-SAE group (P = 0.08).
Discussion
With the widespread use of cross-sectional imaging, most (~80%) AMLs are detected incidentally [14] . Although Table 2 Intraoperative and postoperative results. surveillance is the first-line option for most newly diagnosed AMLs [7] , selected patients with large tumours and those who develop symptoms should be considered for intervention [2] . Traditionally, AMLs were treated surgically [15] , but the management options have expanded and currently SAE, ablative therapy and medical treatment [mammalian target of rapamycin (mTOR) inhibitors; approved for patients with a history of tuberous sclerosis] are available treatment options.
Most data regarding AML treatment outcomes are derived from retrospective studies of NSS and SAE. While most contemporary SAE series include patients who underwent embolisation of large and often symptomatic AML, NSS series include relatively small, incidental renal masses, many of which were found to be AML on surgical pathology [4, 16] . Moreover, there is a paucity of literature on RAPN for AML. It is in this context that we analysed a multi-institutional cohort of patients who were diagnosed with large or symptomatic AMLs and underwent RAPN for their lesions.
The present series supports a favourable morbidity profile and short-term early efficacy of RAPN for the treatment of large AML (median size, 7.2 cm). The overall complication rate was 15% with only one patient (2.5%) experiencing a Clavien-Dindo Grade III complication. The median EBL was 200 mL, and four patients (10%) received blood transfusion after RAPN. Conversion to radical nephrectomy was not required in any patient. During the follow-up period, no patients developed recurrent AML or related symptoms. Furthermore, renal function preservation rate was 95%. SAE before RAPN did not appear to adversely affect intraoperative or postoperative outcomes.
Perioperative outcomes of the present series are similar or more favourable, compared to contemporary open and minimally invasive NSS series for AML. In one of the largest studies, Boorjian et al. [9] analysed a cohort of 58 patients who underwent open PN for AMLs with a median tumour size of 3.9 cm. Their overall complications rate was 12%. Three patients (5%) required interventions (Clavien-Dindo Grade III); one patient underwent postoperative SAE for haemorrhage and two patients were treated for urinary leaks. The median EBL was 350 mL, 23% of patients received blood transfusions and the length of stay was 6 days on average. Our present series appears to be associated with less blood loss (EBL 200 mL), lower transfusion rate (10%) and shorter hospital stay (2 days). These well-established benefits of minimally invasive PN [17, 18] have not been hampered by the large size of the AMLs in our present patient cohort.
Current literature includes a few small, single-institutional case series of minimally invasive PN for AML. Msezane et al. [10] reported on 14 patients who underwent laparoscopic PN for AML with a median size of 2 cm. The operative time, ischaemia time, EBL, complications rate, transfusion rate and length of stay were similar to our present results, at 191 min, 26 min; 215 mL, two of 14 patients, one of 14 patients, and 2.3 days, respectively. However, only five of the 14 patients in their cohort had preoperative diagnosis of AML, with most patients presenting with suspicious small renal masses. Recently, Kara et al. [19] published a series of 53 patients with AML who underwent RAPN. However, in that study most of the patients (79%) were treated for suspicious small renal masses, as reflected by a median tumour size of 2.8 cm. A subgroup of 11 patients (21%) were diagnosed with and treated for AML (median size 5 cm), but perioperative and follow-up data for this specific subgroup were not provided. Compared to our present study, operative time and ischaemia time seem to be shorter (169 and 17.5 min, respectively) but other results were comparable (EBL 198 mL, transfusion rate 9.4%, postoperative complications rate 15% and hospital stay 3 days).
While off-clamp minimally invasive PN for large renal masses has been associated with increased blood loss and postoperative complications compared to small (<4 cm) renal masses [20] , we did not observe such adverse outcomes. It is possible that the use of argon-beam coagulation and previous SAE assisted in maintaining haemostasis in our present series. Considering that the intra-procedural success rates of SAE are very high (see below), it is possible that preoperative transarterial embolisation of large AMLs could reduce intraoperative bleeding and postoperative complications. Further investigation is required to better evaluate this hypothesis.
The morphology of AML makes its resection different than the resection of other solid masses. Finding a dissection plane between the AML and normal parenchyma can be challenging because there is no obvious capsule that may be evident in other renal masses. Conversely, there is no significant neovascularisation or desmoid reaction infiltrating the normal renal parenchyma around the AML. This allowed us, in some cases, to start the dissection with a vessel loop around the hilum but without clamping. The vessel loop was cinched only if bleeding was obstructing the view, as the dissection continues deeper into the parenchyma. This assisted in maintaining ischaemia time, comparable to previous studies, despite significantly larger AMLs.
Any treatment method for renal AML should have a durable control of symptoms, low recurrence rate, and maximal preservation of renal function. In their open NSS study, Boorjian et al. [9] provided valuable information about the long-term effectiveness of the surgical approach. At a median follow-up of 8 years only two patients (3.4%) had radiographic evidence of AML (<1 cm in size). There was no significant change in renal function after surgery and none of the patients developed new onset chronic renal insufficiency. The effectiveness of minimally invasive PN seems to be high as well, albeit the available follow-up time is shorter 758 © 2016 The Authors BJU International © 2016 BJU International (7-15 months) [10, 19] . In the RAPN series by Kara et al. [19] , none of the patients had a recurrence and eGFR preservation was 90%. Consistent with that, in the present study we did not observe AML or symptoms recurrence during follow-up (median 8 months). There was no new onset CKD and the renal preservation rate was 95%.
Underscored by its minimally invasive nature, SAE has been widely adopted for the elective treatment of AML [15] . Although intra-procedural success rates (occlusion of arterial inflow) are as high as 93%, intermediate-term re-treatment rates are 20-40%, suggesting incomplete embolisation. Additionally, longer term (>5 years) data are lacking [4, 8] . The leading indications for re-treatment are recurring pain or bleeding (31%), revascularisation of the AML (30%), and failure to reduce AML size (23%) [8] . In our present study, 11 patients (28%), with a median AML size of 8 cm, who failed SAE were successfully treated with RAPN. None of these patients required radical nephrectomy or had ClavienDindo Grade ≥III complications. There was no reduction in renal function and no symptom recurrence (Table 3 ). These data suggest that RAPN is a viable treatment option for patients with large AML and can be safely performed either primarily or secondarily (after SAE failure) with good surgical outcomes.
Our present study is limited by its retrospective nature and relatively short follow-up. Indeed, previously published series of open PN showed the long-term effectiveness of the surgical approach [9] , but this requires verification by data from minimally invasive series. Another limitation is the selection against lipid-poor AMLs. We focused on lipid-rich AML, which can be reliably diagnosed by cross-sectional imaging and represent the vast majority of newly diagnosed AML. Considering the excellent accuracy of modern imaging in the diagnosis of lipid-rich AML [21] , surgical margins are of less importance and were not reported in the present study. Finally, there is growing evidence that most patients with asymptomatic AMLs of >4 cm may not require early intervention [6] . We support surveillance as the first-line option for appropriately selected patients. Despite these limitations, our present study is one of the few to report the results of NSS for patients who were diagnosed with large AML before surgery and the largest to describe RAPN in this population. It provides valuable information that can be used when discussing treatment options with symptomatic patients or with patients who pursue treatment to minimise any risk of developing AML-related complications.
Conclusions
Robot-assisted partial nephrectomy (RAPN) for the elective treatment of large AML appears to be safe with a favourable perioperative morbidity profile and high renal function preservation rates. All patients remained free of symptoms after RAPN, but longer follow-up is required to assess therapeutic efficacy. SAE before RAPN did not appear to have any adverse impact on treatment outcomes. Therefore, RAPN should be considered as a primary or secondary (post-SAE) treatment option for patients with large or symptomatic AMLs.
